Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Shandong Cancer Hospital and Institute
First Affiliated Hospital of Zhejiang University
Ohio State University Comprehensive Cancer Center
Khon Kaen University
University of Chicago
University of Wisconsin, Madison
Vanderbilt-Ingram Cancer Center
UNICANCER
Federation Francophone de Cancerologie Digestive
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center